CAR-T for Acute B-cell Lymphoblastic Leukemia(B-ALL)

B-ALL (Acute B-cell Lymphoblastic Leukemia) is an aggressive form of leukemia, primarily affecting children and young adults. Despite advances in traditional chemotherapy, many patients experience relapse or treatment resistance. CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a groundbreaking immunotherapy that has shown remarkable success in treating relapsed or refractory B-ALL, offering hope for patients who previously had limited treatment options.

CAR-T therapy is an advanced, personalized treatment that involves modifying a patient's own T-cells to recognize and attack cancer cells. For B-ALL, CAR-T cells are engineered to target the CD19 antigen, a protein commonly found on the surface of B-cell leukemia cells. Once infused back into the patient’s body, these engineered T-cells seek out and destroy the leukemia cells, potentially leading to long-lasting remission.

• High Efficacy: CAR-T therapy has demonstrated impressive success in treating relapsed or refractory B-ALL, offering a high rate of remission in patients who have not responded to traditional treatments.
• Targeted Action: By focusing on the CD19 antigen, CAR-T therapy specifically targets and destroys B-ALL cells, minimizing damage to healthy tissues.
• Personalized Treatment: Since CAR-T cells are derived from the patient's own immune system, the therapy is highly personalized, increasing its effectiveness and reducing the risk of rejection.
• Durable Remission: In many cases, CAR-T therapy has led to durable remission, offering patients the potential for long-term survival with fewer relapses.

• Collection of T-cells: The first step involves collecting T-cells from the patient's blood through a process called leukapheresis.
• Engineering T-cells: The collected T-cells are genetically modified in the laboratory to express a chimeric antigen receptor (CAR) specific to CD19, enhancing their ability to target B-ALL cells.
• Infusion of CAR-T Cells: After a brief period of cell expansion, the engineered CAR-T cells are infused back into the patient's body through an intravenous (IV) infusion.
• Monitoring and Recovery: Post-infusion, patients are closely monitored for potential side effects such as cytokine release syndrome (CRS) and neurotoxicity. These reactions are generally manageable, and the majority of patients recover with appropriate interventions.

• State-of-the-Art Technology: BIOOCUS uses cutting-edge technology to ensure optimal CAR-T cell production and patient outcomes.
• Expert Medical Team: Our team of specialists in hematology and immunotherapy is dedicated to providing personalized care and maximizing the success of each treatment.
• International Experience: We offer CAR-T therapy to patients from around the world, with a track record of successful treatments and long-term remission for B-ALL patients.
• Comprehensive Care: From initial consultation through to follow-up monitoring, BIOOCUS provides full-spectrum care, ensuring patients receive the best possible treatment at every stage.

Recent clinical trials and real-world data have shown that CAR-T therapy for B-ALL offers exceptional results, particularly for patients who have relapsed or are resistant to traditional treatments. The therapy has consistently demonstrated high remission rates, with many patients achieving complete remission and maintaining long-term survival.

At BIOOCUS, we have successfully treated numerous patients with B-ALL using CAR-T therapy, and the outcomes have been overwhelmingly positive. For a deeper understanding of the success stories and real-life outcomes, please explore the following patient case studies:

• Patient Story: High-Risk B-ALL, Bone Marrow Transplant at 9 Months—Two Years Later, A Healthy Start
• From Initial Graft Failure to Full Recovery: A Patient's Journey with Lu Daopei's Advanced Transplant
• Acute Lymphoblastic Leukemia (B-ALL) Product Information and Case Studies

These cases highlight the transformative potential of CAR-T therapy for B-ALL patients, showcasing not only the treatment's efficacy but also its capacity to offer patients a second chance at life.